Advancing Cardiac Care: A Registry of Heart Transplantation in Latin America (1968-2022).

INTRODUCTION: Heart transplantation (HTx) has emerged as a pivotal intervention for end-stage heart failure, offering significant improvements in survival and quality of life. This manuscript elucidates the landscape of HTx across Latin America (LATAM) from its advent in 1968 through December 2022, shedding light on its evolution, current practices, and regional disparities. METHODS: We distributed a structured questionnaire to the national coordinators or representatives of the Interamerican Council of Heart Failure and Pulmonary Hypertension, collating responses from 20 LATAM nations. This approach facilitated a comprehensive aggregation of regional HTx data. RESULTS: A total of 12,374 HTx were performed in 166 centers across 16 LATAM countries, with Brazil, Argentina, and Colombia accounting for the majority of procedures. Pediatric transplants represented 9% of the total caseload, and combined organ transplants were reported in 62.5% of the participating countries, underscoring the complexity and breadth of transplant services in the region. CONCLUSION: Despite facing infrastructural and logistical challenges, LATAM has demonstrated a robust capacity to conduct high-complexity transplant procedures. The establishment of a structured, regional HTx registry is imperative to enhance data collection and analysis, which in turn can inform clinical decision-making and policy development, ultimately improving patient outcomes across the continent.

First successful implant of BiVACOR's Total Artificial Heart.

BiVACOR's Total Artificial Heart has been successfully implanted in a patient at Baylor St. Luke's Medical Center in the Texas Medical Center. The patient survived with the device for 8 days before receiving a heart transplant. This success stemmed from collaboration between BiVACOR Inc. and a team of cardiac surgeons at the Texas Heart Institute, including William E. Cohn, M.D., and Oscar H. Frazier, MD.

Nothing like a good feud to spark competition: First use of the total artificial heart.

As a native Houstonian, the notoriety surrounding Dr. Denton A Cooley's implantation of the total artificial heart on Good Friday, April 4, 1969, was inescapable. At the time, Drs. Cooley and Michael E. DeBakey were the two most famous surgeons in Houston and much of the world. They had worked together professionally for 18 years, revolutionizing cardiothoracic surgery and mastering aortic surgery from beginning to end. However, this working relationship ended abruptly, and one of the most famous feuds in medicine began. Little did I know at the time that I would train with both men, work in both their respective institutions (which are located on the most competitive block of the Texas Medical Center), and play a role four decades later as their relationship rekindled. Here, I recount what I have come to learn about these events.

Race, Kidney Transplants, Immunosuppression Research, and White Supremacy under Apartheid, 1960-80.

This paper uses the history of kidney transplantation in South Africa as a lens through which to write a racialized, micro history that illustrates the politics of medical discoveries and medical research at one of South Africa's most prestigious medical research universities, the University of the Witwatersrand (Wits) in Johannesburg. Between 1966 and the 1980s, the Wits team became the most advanced and prolific kidney transplant unit in the country. Yet the racist, oppressive Apartheid system fundamentally shaped these developments. Transplantation, as this paper shows, became an elite medical procedure, performed by a select group of white doctors on mostly white patients. For these doctors, transplantation showed their medical prowess and displayed the technical advancements they were able to make in research and clinical practice as they strove to position South Africa as a significant international player in medical research, despite academic boycotts and increasing sanctions. Transplantation became a symbol of white supremacy in a country where the black majority were excluded from anything but the most basic health care.

Leo Fabian: A Life of Accomplishment.

Leo Fabian played a role in many anesthesia firsts: the first halothane anesthetics in the United States, the first American electrical anesthetic, the first lung allotransplant, and the first heart xenotransplant. As was common for men of his generation, Fabian's first taste of medicine came during World War II, as a pharmacist's mate aboard the U.S.S. Bountiful. Afterward, he pursued his medical education before joining Dr. C. Ronald Stephen and the anesthesiology department at Duke. There he helped to create one of the first inhalers for halothane, the Fabian Newton Stephen (F-N-S) Fluothane Vaporizer. Fabian left Duke for the University of Mississippi Medical Center, where he consistently worked with the chair of surgery, Dr. James Hardy. Together they performed the first American electrical anesthetic, the first lung allotransplant, and the first heart xenotransplant. By the end of his time at Mississippi, Fabian and Hardy had several philosophical disagreements, and Fabian ultimately left for Washington University in St. Louis, where he rejoined Dr. Stephen. He served as Stephen's right-hand man and would oversee the department when Stephen was away. Fabian spent the final years of his career as chair of the department before his own health forced him to step down.

Solid Organ Transplantation Activities Evolution in Brazil: Analysis of 20 Years.

BACKGROUND: From 1968 until 1997, transplantation-related activities were not properly regulated and were informally practiced. During 20 years, many legal and political changes influenced it. OBJECTIVE: To provide a historical overview of the 20 years with a descriptive data analysis of a 20-year data set. METHODOLOGY: We investigated information from Brazilian Transplantation Reports between 1997 and 2017. In this way, we classified all data into 5 Brazilian macro regions: Center-West, Northeast, North, Southeast, and South. In total, we included 27 states (including Capital District) and limited study to the heart, liver, and kidney. RESULTS: We analyzed 2835 data entries and associated population information from the Brazilian Institute of Geography and Statistics. We observed 2 distinct groups, one uniquely formed by the North region, with figures significantly lower than the remaining regions. After 2003, Southeast, South, and Northeast regions indicated a growing movement, whereas Center-West indicated certain stability in 50 and ranging between 50 and 100 cases (yearly basis) after 2011. Recently (2016 and 2017), the South region indicates another crescendo movement suggesting another detachment from the other regions, but it is something not clearly observed and, if true, should be figured in new reports of Brazilian Association of Organ Transplantation. CONCLUSION: This study identified and observed the time-spatial progress of organ transplantation in Brazil. In conclusion, after analysis of this 20-year data consolidation related to organ transplantation in Brazil, we observed a public investment in implementing quality evaluation and safety to provide figures that deliver visibility to the numbers reported in this article.

Fiftieth anniversary of the first heart transplantation in Switzerland in the context of the worldwide history of heart transplantation.

On 3 December 1967, Christiaan Barnard performed the first heart transplantation in the world at Groote Schuur Hospital in Cape Town, South Africa. In the succeeding months, heart transplantations in the USA, Asia and Europe followed. On 14 April 1969, Åke Senning successfully accomplished the first heart transplantation in Switzerland at the former Cantonal Hospital in Zurich. In the summer of 1969, he undertook a second heart transplantation. Although the surgical procedure went well technically, both patients died within weeks to months after transplantation. Causes of death were infection in the first and rejection in the second patient. Senning’s colleagues around the world had similar experiences. Survival after heart transplantation was unacceptably low. The heart transplant community recognised the lack of knowledge about immunological processes and appropriate immunosuppressive regimens as underlying reason for the early deaths. Most transplant centres decided to refrain from heart transplantation until sufficient immunological insight became available. After the introduction of the new immunosuppressive drug ciclosporin into the clinic and the availability of tools to monitor rejection in the early 1980s, heart transplant programmes were restarted all over the world. The legal recognition of brain death allowed procurement of donor hearts without exposure to warm ischaemia, and the principle of cold storage enabled prolongation of ischaemia time and acceptance of donors in distant hospitals, resulting in enlargement of the donor pool. In Switzerland, Marko Turina resumed heart transplantation in 1985 at Senning’s former workplace in Zurich. The number of heart transplants in Switzerland and in the world grew rapidly because the outcome markedly improved. Particularly over the long-term, survival in Zurich surpassed the outcome worldwide. Zurich created internationally recognised milestones such as transplantation of patients with grown-up congenital heart disease, the implementation of the bicaval instead of the right atrial anastomosis during the transplant procedure and the dual transplantation of one heart. Since the middle of the 1990s, however, the number of heart transplants has plateaued, mainly because of donor shortage. The current era is characterised by efforts to increase the number of donors. The utilisation of marginal donors, the change from informed to presumed consent for organ donation and donation after cardiocirculatory-determined death have been proposed to augment the donor pool.

Commemorating 50 years since the first heart transplantation in Bratislava - Czechoslovakia.

The first human-to-human heart transplantation in Czechoslovakia, and the 25th transplantation in the world, was performed in Bratislava, the second largest city in Czechoslovakia on July 9, 1968. The operation was carried out by a team led by Professors Karol Siska and Ladislav Kuzela at the second Surgical Clinic at the Comenius University of the Medical Faculty in Bratislava, Partizanska Street-only seven months after the first heart transplantation performed by Dr. Christiaan Barnard in Cape Town. Other members of the team in Bratislava included surgery recipients Siska, Kuzela, Pivkova, Holoman; surgery donors Schnorrer, Kuzela, Holoman; an extracorporeal circulation team of Treger, Carsky, Podolay; anesthesiologists Sobesky and Neumanova; operating room nurses Machkova, Homerova, Kralova, and operating room laboratory technician Malinova. The donor was P.V., a 46-year-old man, who suffered from a deadly brain trauma. The recipient was S.H., a 54-year-old woman with a failing heart, heavily affected diseased lungs, kidneys and liver. Her heart began to work, but lasted only for five hours. (Additional members of the team, Prof. Simkovic and Drs. Silvay and Sujansky were in the USA at the moment of transplantation, in Houston and New York, subsequently) (Tab. 1, Fig. 2, Ref. 62). Keywords: first heart transplantation in Bratislava, 2nd Surgical Clinic at the Comenius University.

The first successful pediatric heart transplant and results from the earliest era.

BACKGROUND: The first pediatric heart transplant died 5 hours after transplant and the case was published by Kantrowitz. There is no report of the first successful case in the medical literature, nor indeed the outcome of children transplanted prior to 1982. However, we recently discovered that children from this period were entered retrospectively into the ISHLT Registry when it began and they form the basis of this report. METHODS: A retrospective review of the ISHLT Thoracic Registry was undertaken for pediatric heart transplants prior to 1982. Demographic and descriptive data, and patient and graft survival were analyzed. RESULTS: Thirty children (24 male) had a median age of 13 years (IQR 12-16) at the time of primary transplant. The underlying cardiac diagnosis was cardiomyopathy (18), congenital heart disease (7), not reported (5). The median follow-up was 2.63 years (IQR 0.1-7.2). Twenty-two patients are known to have died, and eight underwent retransplantation. Median patient survival was 3.5 years. The first patient to survive for more than one year was transplanted in 1968 and survived 6 years. CONCLUSION: The definition of a successful transplant is debatable; however, the first child reported to the registry to survive beyond one year was transplanted in 1968. Survival for these early patients was considerably less than the subsequent eras and retransplantation more common; however, the experience in managing these children laid the foundation for the future.

[50 Years ago: First Successful Treatment of Acute Allograft Rejection after a Human Heart Transplantation]. / Vor 50 Jahren: Erste erfolgreiche Behandlung einer akuten Herztransplantat-Abstoßungskrise.

The first clinical use of the "Munich antilymphocyte globulin" (ALG) at the occasion of the first successful human heart transplantation is briefly described. The cardiac transplantation was carried out by Christiaan Barnard and his team in Cape Town, South Africa, in 1968. The patient developed an acute allograft rejection which could be successfully reversed within three weeks using the intravenous administration of ALG. This event can be regarded as the beginning of a success story of ALG in its use as a powerful immunosuppressive agent in all categories of clinical organ transplantation.